These reports demonstrate potential adverse effects of Raf inhibitors depending on the tumor genotype, such as the paradoxical activation of C-Raf and the downstream MEK-ERK pathway in tumor cells expressing mutant Ras. Here, RAF1 is linked to neoplasm.